Net Income (Loss) Per Ordinary Share

9 Months Ended

Sep. 30, 2025

Net Loss Per Ordinary Share

Net loss per ordinary share was determined as follows (in thousands, except per share amounts):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Numerator:
Net loss	$	(36,541)	$	(59,001)	$	(222,503)	$	(64,354)
Denominator:
Weighted-average ordinary shares outstanding used in per share calculations	53,830		53,790		53,828		53,757
Net loss per share:
Basic and diluted net loss per ordinary share	$	(0.68)	$	(1.10)	$	(4.13)	$	(1.20)

Potentially issuable ordinary shares were not used in computing diluted net loss per ordinary share as their effect would be anti-dilutive due to the loss recorded during the three and nine months ended September 30, 2025 and 2024, and therefore diluted net loss per share is equal to basic net loss per share.

The equivalent ordinary shares not included in diluted net income (loss) per share because their effect would be anti-dilutive are as follows (in thousands):


	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Stock options to purchase ordinary shares	11,627	11,297	11,627	11,297
Restricted Stock Units (RSU)	1,133	24	1,133	24
Total	12,760	11,321	12,760	11,321

PROTHENA CORP PUBLIC LTD CO 10-Q